This guide outlines essential knowledge for pharmaceutical quality assurance managers about subvisible particle testing requirements, technology selection, and the development of a compliant, inspection-ready program.
USP <788> and <789> establish mandatory compendial thresholds for particulate matter, serving as enforceable standards. USP <1788> serves as an informational companion, detailing best practices for testing and highlighting the advantages of supplementary methods such as dynamic image analysis (DIA).
Understanding their interplay is vital for any quality assurance program managing parenteral or ophthalmic products.
The significance of subvisible particles as a critical quality attribute
Subvisible particulate matter, generally characterized as particles within the 1 to 100 µm range, is among the most rigorously examined quality attributes in sterile drug manufacturing. These particles are undetectable to the human eye yet sufficiently large to pose immunogenicity risks, particularly in biological drug formulations.
For quality assurance managers, the implications are substantial across multiple domains: regulatory submissions necessitate compliant data, product release and stability assessments must meet compendial limits, and investigations into deviations increasingly demand the identification of particles, not solely their quantification.
Key contextual information
The analysis of subvisible particles has grown more complex with the proliferation of biologics. Protein aggregates, silicone oil droplets originating from prefilled syringes, and rubber particles resulting from stopper interactions are common in contemporary formulations.
Light obscuration alone cannot differentiate between these various particle types; this is a primary regulatory challenge that USP <1788> aims to address.
What constitutes a subvisible particle?
Compendial chapters use size thresholds of ≥ 10µm and ≥25 µm for limit testing. Dynamic image analysis facilitates characterization down to 1–2 µm, yielding richer data for investigations and method development. Particles exceeding 100 µm are typically addressed by visible particle inspection protocols under USP <790> and <1790>.
Interrelationship of USP chapters
The USP framework for subvisible particle assessment is structured across several chapters, each with distinct responsibilities. Identifying which chapters represent enforceable requirements versus informational guidance is the foundational step for any compliance initiative.
Source: Vision Analytical Inc.
| Chapter |
Title |
Type |
Scope |
| USP <787> |
Subvisible Particulate Matter in Therapeutic Protein Injections |
Compendial |
Therapeutic proteins; uses the same LO/MPC methodology as <788> but with tighter limits and specific guidance for protein aggregates |
| USP <788> |
Particulate Matter in Injections |
Compendial |
All parenteral injections; primary LO and MPC limits for ≥10 µm and ≥25 µm |
| USP <789> |
Particulate Matter in Ophthalmic Solutions |
Compendial |
Ophthalmic solutions; separate, more stringent particle limits |
| USP <790> |
Visible Particulates in Injections |
Compendial |
Visual inspection requirements for particles >100 µm |
| USP <1788> |
Methods for the Determination of Subvisible Particulate Matter |
Informational |
Guidance on how to apply LO, MPC, and flow imaging/DIA methods correctly and when to use orthogonal approaches |
| USP <1788.3> |
Flow Imaging/
Dynamic Image
Analysis |
Informational |
Sub-chapter of <1788> providing specific technical guidance for image-based particle analysis systems |
| USP <1787> |
Measurement of Subvisible Particulate Matter in Therapeutic Protein Injections |
Informational |
Companion to <787>; guidance on risk assessment for protein aggregates |
Compendial chapters (designated by numbers below <1000>) establish mandatory limits. Informational chapters (chapter <1000> and higher) provide guidance on best practices and are not independently enforceable. However, regulators increasingly cite them in audit discussions and warning letters, thereby lending them significant practical importance.
USP <788>: Particulate matter in injections
USP <788> serves as the fundamental compendial chapter concerning particulate matter in parenteral drug products. It defines the acceptable particle thresholds that must be satisfied for release testing and constitutes a standard requirement in regulatory submissions for injectable drugs.
Source: Vision Analytical Inc.
| Product Type |
≥ 10 µm limit |
≥ 25 µm limit |
Test Method |
| Large-volume injections (> 100 mL) |
≤ 25 particles/mL |
≤ 3 particles/mL |
Light Obscuration (primary) |
| Small-volume injections (≤ 100 mL) |
≤ 6000 particles/container |
≤ 600 particles/container |
Light Obscuration (primary) |
| When LO is not suitable (e.g., viscous, opaque) |
≤ 3000 particles/container |
≤ 300 particles/container |
Membrane Particle Count (MPC) |
Situations where light obscuration may not be suitable
USP <788> expressly recognizes that light obscuration may not be appropriate for all formulations. Membrane particle count (MPC), which involves microscopic examination of particles collected on a filter membrane, is the alternative compendial method when LO is impractical. This is frequently encountered with:
- Highly viscous formulations (e.g., certain biologics, hyaluronic acid products)
- Inherently colored or turbid solutions
- Products containing air bubbles that cannot be removed without sample degradation
- Emulsions and liposomal formulations
Should a formulation consistently yield LO data that fails system suitability due to matrix interference, documenting the scientific justification for transitioning to MPC is crucial. USP <1788> offers the evidentiary basis for such a decision.
System suitability requirements
Prior to any test execution, USP <788> mandates system suitability verification using calibrated particle standards. The instrument must demonstrate its capacity to accurately count and size particles within specified tolerances.
Failure to pass system suitability invalidates the test run, a common contributor to out-of-specification (OOS) investigations when not subject to procedural controls.
USP <789>: Particulate matter in ophthalmic solutions
USP <789> applies specifically to ophthalmic drug products, including eye drops, irrigation solutions, and similar preparations that come into contact with ocular tissue. The limits imposed are significantly more stringent than those in <788> due to the sensitivity of ocular tissues and the inherent risk of irritation or injury from particulate matter.
Source: Vision Analytical Inc.
| Product Type |
≥ 10 µm limit |
≥ 25 µm limit |
| Ophthalmic solutions (≤ 1 mL) |
≤ 50 particles/mL |
≤ five particles/mL |
| Ophthalmic solutions (> 1 mL) |
≤ 25 particles/mL |
≤ three particles/mL |
The methodology outlined in <789> mirrors that of <788>; light obscuration is the primary method, with membrane particle count serving as the alternative. The same guidance for method selection and orthogonal analysis as provided in USP <1788> is applicable.
Ophthalmic products are gaining increasing relevance for advanced biologics. Intravitreal injections (e.g., anti-VEGF therapies, gene therapy vectors) fall under the purview of <789> and present similar challenges for protein aggregate characterization as encountered with parenteral biologics. The rationale for employing orthogonal imaging techniques is equally compelling in these applications as it is in <788> contexts.
USP <1788>: Methods for subvisible particle analysis
USP <1788> functions as the informational chapter guiding analysts and quality assurance managers on how to execute particle testing effectively, going beyond merely meeting specified limits. It encompasses all three analytical categories: light obscuration, membrane particle count, and flow imaging/dynamic image analysis.
Central themes in USP <1788>
- Orthogonal methods are expected: No single technology fully characterizes all particle types; USP explicitly recommends the use of complementary methods, particularly for biologics and complex formulations.
- Sample handling is critical: Factors such as mixing, temperature, container type, and environmental controls can substantially alter results. The chapter provides guidance on minimizing pre-analytical variables.
- Method-dependent differences are normal: Different technologies will yield varying counts for the same sample. This is an expected phenomenon and should be explained during method validation, rather than being treated as a discrepancy.
- Particle identity is important: Counting particles is necessary but not sufficient. Identifying whether particles are protein aggregates, silicone oil droplets, foreign matter, or inherent excipient particles is essential for making appropriate quality decisions.
About Vision Analytical Inc.
Vision Analytical is an established company focused on Particle Size, Count, Shape, Concentration, and Classification using Dynamic Image Analysis. Our mission is to create superior, customer-focused solutions and services to deliver tangible economic impact through physical analysis of raw materials using image analysis of particles. Our product line of instruments helps users better understand a wide variety of materials in a broad spectrum of industries, from industrial to life science industries.
Our core technology, Dynamic Image Analysis, allows for more details to be obtained from raw materials than just size. This robust characterization method allows for a better understanding of how particles will behave, concentration analysis, and other properties not available in size-only instruments.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.